Back to results
US 2022/0017485 A1Published application
Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
AssigneeUnity Biotechnology, Inc.
InventorsAnne-Marie Beausoleil, Ryan Hudson
Life of this patent
Estimating the term…
Abstract
The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
Claims20
A compound according to formula (I):
- wherein:
- X1 is —Cl;
- X2 is —COOH;
- X3 is —SO2CF3;
- —SO2CH3;
- or —NO2
- X5 is —F or —H;
- R1 is —CH(CH3)2;
- R2 is —CH3,
- R3 and R4 are both —H;
- n1 is 2;
- and
- R6 is selected from —OH,
- wherein the hydroxyl group in R6 is optionally phosphorylated,
- with the proviso that if X3 is —SO2CF3, then the hydroxyl group in R6 must be phosphorylated.
12 more elements
Dependencies are inferred from the claim text.